Latest Racing News

Structural Monitoring Systems’ subsidiary AEM has won full US Forest Service approval for its MTP136D radio, enabling deployment across all federally regulated US aerial firefighting aircraft and setting the stage for significant growth in 2025.

Amaero has completed a A$22 million institutional placement, concluding nearly A$100 million raised since 2022 and positioning itself for commercialisation in FY2026 with a robust balance sheet.

KALINA Power has significantly expanded its land holdings in Alberta, boosting its potential Power-CCS capacity to 1.7 GW to meet surging demand for data centre power solutions with carbon capture.

Arizona Lithium has unveiled a detailed, phased development plan for its Prairie Lithium Project, aiming to become North America’s first commercial lithium brine producer. The company targets initial production in 2025 with a modest capital outlay and scalable expansion strategy.

BlueBet Holdings Ltd has announced the acquisition of TopSport, a strategic move expected to boost its market share and profitability. The deal is supported by a $15 million equity raising to fund the upfront payment and growth initiatives.

BlueBet has announced a strategic acquisition of TopSport, supported by a $15 million equity raise, aiming to boost market share and deliver significant earnings accretion by FY26.

Meteoric Resources reports exceptional rare earth element grades and enriched magnetic rare earth oxides at its Agostinho Prospect in Brazil, signaling a potential expansion of its Caldeira Project resource base.

Top End Energy has completed its acquisition of Serpentine Energy, securing a strategic natural hydrogen project in Kansas and gearing up for exploration drilling in the second half of 2025.

Environmental Clean Technologies Limited has formed a joint venture and launched field trials for its innovative COLDry lignite-nitrogen fertiliser, marking a pivotal step toward commercialisation and revenue generation.

BetMakers Technology Group reports a sharp 69% reduction in adjusted EBITDA loss and a 43% improvement in operating cash flow for Q2 FY25, marking a pivotal shift from restructuring to growth. The company’s successful Apollo platform migration and cost-cutting initiatives underpin a confident outlook for revenue expansion.

Race Oncology has advanced its Phase 1 clinical trial for RC220, submitting ethics approvals and bolstering its cash reserves to $18.78 million following a $5.25 million R&D tax incentive.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.